Semax Research
Synthetic ACTH Analog & Neuropeptide
cognitive signaling research
Stress and Anxiety
Solo información educativa. Los usos de investigación pueden no tener aprobación de la FDA. No es asesoramiento médico ni un plan de tratamiento.
Semax is a synthetic heptapeptide analog of the ACTH(4–10) fragment, developed in Russia where it has been studied and used clinically. Unlike ACTH itself, it has no adrenocortical activity. Researchers study it for its effects on cognitive signaling, neuroprotective pathways, and neurotrophin regulation.
Áreas de investigación
BDNF & Neurotrophin Signaling
Studies investigate Semax's ability to upregulate brain-derived neurotrophic factor (BDNF) and other neurotrophin expression pathways, exploring its role in neuronal survival, synaptic plasticity, and neurogenesis-related signaling.
Cognitive & Memory Pathway Research
Research examines its influence on attention, working memory, and learning-related signaling pathways, including hippocampal function and cholinergic neurotransmission research.
Neuroprotective Signaling
Studies explore Semax's potential protective effects on neurons under ischemic or oxidative stress conditions, investigating anti-apoptotic signaling pathways and neuroinflammation modulation research.
Dopaminergic & Serotonergic Pathway Research
Researchers study its interaction with dopamine and serotonin receptor signaling systems, including its influence on mood-related neurotransmitter pathways and receptor sensitivity research.
HPA Axis & Stress Response Research
Research investigates Semax's modulation of hypothalamic-pituitary-adrenal axis signaling, cortisol-related pathways, and stress-adaptation signaling in animal models.
Approved as a drug in Russia; investigational in most other regions. Not FDA-approved. Not medical advice.
¿Tiene preguntas sobre Semax?
Solicite una consulta gratuita para hacer preguntas y aprender más sobre esta área de investigación.
Solicitar una consulta gratuita